Clinical trials
Phase 1/2 Insulin Resistance trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2017 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adrian Vella | 1 |
| Albert Einstein College of Medicine | 1 |
| Alnylam Pharmaceuticals | 1 |
| Altea Therapeutics | 1 |
| Brigham and Women's Hospital | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Duke University | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Milton S. Hershey Medical Center | 1 |
| National Center for Complementary and Integrative Health (NCCIH) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insulin Resistance | 20 |
| Obesity | 7 |
| Diabetes Mellitus, Type 2 | 4 |
| Diabetes Mellitus | 3 |
| Metabolic Syndrome | 3 |
| Diabetes Mellitus, Type 1 | 2 |
| HIV Infections | 2 |
| Prediabetic State | 2 |
| Body Weight Changes | 1 |
| Breast Neoplasms | 1 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.